Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | COC[C@H](C)n1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |r,wU:3.3,(49.23,-29.16,;50.01,-30.49,;51.55,-30.48,;52.33,-31.81,;51.56,-33.15,;53.87,-31.8,;54.77,-30.54,;56.25,-31.01,;57.57,-30.25,;58.91,-31.01,;60.24,-30.24,;58.91,-32.56,;60.25,-33.33,;61.58,-32.55,;57.58,-33.33,;57.58,-34.87,;56.24,-35.63,;56.24,-37.17,;57.57,-37.95,;57.57,-39.49,;58.91,-37.17,;58.91,-35.64,;60.24,-34.86,;56.25,-32.56,;54.78,-33.05,;54.31,-34.52,)| |